1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Prosecution Takes Over Case of 8 Medics Pinned for Misusing Covid-19 Vaccines

01/17/2022 | 02:06am EDT

Rwanda Investigation Bureau (RIB) has confirmed it has submitted to the National Public Prosecution Authority the case of eight health workers, who were arrested over embezzling Covid-19 kits and misuse of vaccines.

According to RIB spokesperson, Thierry B. Murangira, the suspects were arrested between January 4 and 8.

The suspects are from at least three health centres; Kinunu, Nyabirasi and Biruyi health centers in Rustiro district.

Others are from Nyanza District, at Gatagara Health Post.

Speaking to The New Times Murangira explained that two suspects from Kinunu Health Centre were unable to explain how they used 30 AstraZeneca vaccine bottles which were supposed to vaccinate 300 people.

Other two suspects from Nyabirasi Health Centre failed to explain how they used 45 bottles of Moderna vaccine which were meant to vaccinate 675 people.

"Preliminary investigations revealed that the suspects would go to various vaccination sites and vaccinate people without first checking if the number of people supposed to be vaccinated per bottle, as per instructions," he explained.

He further clarified that one AstraZeneca bottle usually vaccinates 10 people while a Moderna bottle vaccinates 15 people and should last for six hours and 12 hours respectively. Beyond those hours they expire.

However, for some of the suspects, they would open the bottle, vaccinate a few people and after six or 12 hours depending on the type of vaccines, threw bottles away, then opened new ones to vaccinate new people.

"They did not comply with vaccines instructions, those acts are therefore constitute the crime of misuse of property of public interest," Murangira said.

According to Murangira, the other four suspects were arrested on suspicion of embezzlement.

"One suspect from Biruyi Health Centre was arrested for selling four boxes of Covid-19 rapid test kits and a box usually contains 25 pieces," he said.

A test kit costs Rwf5000.

Murangira added that it's the same case to three suspects who were arrested in the Nyanza district where they took 1,750 Covid-19 test kits from CHUB General Hospital in Huye but never delivered them to Nyanza Hospital as expected.

"The undelivered kits cost approximately Rwf6,125,000," Murangira revealed.

RIB urges people to be vigilant, saying that misusing public property will not be tolerated, especially now when the country is dealing with a pandemic.

"People have to avoid such crimes and RIB will not tolerate anyone caught in these crimes," Murangira said adding that "those crimes are related to corruption, and corruption is an imprescriptible crime and punishable by heavy penalties" he added

RIB also calls all public hospitals in Rwanda to conduct in-depth assessments and report unclear cases.

For embezzlement crime upon conviction four suspects are liable for sentencing to a term of imprisonment of not less than seven years but not more than 10 and a fine of Rwandan francs from three to five times the value of the stolen property.

While for misuse of property of the public interest upon conviction suspects are sentenced to between five to seven years imprisonment and a fine not less than Rwf3,000,000 but not more than Rwf5, 000,000.

Copyright The New Times. Distributed by AllAfrica Global Media (allAfrica.com)., source News Service English

Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 0.40% 10588 Delayed Quote.21.92%
MODERNA, INC. 8.73% 147.66 Delayed Quote.-41.86%
All news about ASTRAZENECA PLC
05/27AstraZeneca Doses First Patients in Phase-III Trial Evaluating Anifrolumab in Kidney In..
05/27First Patients Dosed in IRIS Phase III Trial Evaluating Anifrolumab in Lupus Nephritis
05/27ASTRAZENECA : Berenberg keeps its Buy rating
05/26Cancer treatments may benefit from lessons of pandemic set-backs -AstraZeneca executive
05/25ASTRAZENECA : JP Morgan keeps its Buy rating
05/25French health body backs new COVID vaccine booster campaign for this autumn
05/24Indian vaccine giant Serum plans African plant in global expansion
05/24Danske Bank Initiates Coverage on AstraZeneca With Buy Rating
05/24Vaxzevria approved in the EU as third dose booster against COVID-19
05/24AstraZeneca aims to transform cancer care with practice-changing data at ASCO 2022
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2022 43 665 M - -
Net income 2022 5 151 M - -
Net Debt 2022 23 311 M - -
P/E ratio 2022 40,4x
Yield 2022 2,21%
Capitalization 207 B 207 B -
EV / Sales 2022 5,27x
EV / Sales 2023 4,84x
Nbr of Employees 83 100
Free-Float 96,4%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | AZN | GB0009895292 | MarketScreener
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 26
Last Close Price 133,47 $
Average target price 143,66 $
Spread / Average Target 7,64%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC21.92%206 801
NOVO NORDISK A/S-3.80%1 677 391
JOHNSON & JOHNSON5.86%476 521
PFIZER, INC.-8.70%302 483
ROCHE HOLDING AG-13.00%281 098